Floatz logo

Igf-Methotrexate Conjugate

Genitourinary Cancers

IGF Oncology, LLCunclassifiedPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Genitourinary Cancers cohort.

Asset / SponsorPhaseRating
Tadalafil
Regina Elena Cancer Institute
Phase 3B
Nivolumab
Spanish Oncology Genito-Urinary Group
Phase 2B
Ipilimumab
Dana-Farber Cancer Institute
Phase 2B
Atezolizumab
British Columbia Cancer Agency
Phase 2B
Riluzole
University of California, Irvine
Phase 2CCC

View all 31 →

Same molecule, other indications

Igf-Methotrexate Conjugate is also rated in:

Anemia, Refractory, With Excess of BlastsDormant
CCC
Indicative ·
48 / 100
View asset →
Leukemia, Myelomonocytic, ChronicDormant
CCC
Indicative ·
48 / 100
View asset →
thoracic cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →